Recently, Chuangxin International completed a Pre-B round of financing of RMB 100 million. This round of financing was led by Dachen Caizhi, followed by Guangzhou Financial Holdings, Guangzhou Development Zone Fund, Wanlian Securities, Zhonghe Anke, and Qudao Assets and other original investment institutions continued to make additional investments.
The founder of the company, Dr. Huang Min, said that this round of financing reflects the firm confidence of investors in the development of the industry and enterprises. Chuangxin will continue to increase investment in the research and development of core technologies and products and talents, build a technology platform for the whole life cycle of organoids, promote breakthroughs and upgrades in core technologies, and focus on the formation of products such as organoid biomaterials, organoid chips, and artificial intelligence systems. Matrix and industrial chain layout. At the same time, Chuangxin will continue to deepen commercial transformation and market expansion, and provide standardized solutions for clinical patients in the direction of precision treatment; in the field of new drug research and development, Chuangxin is committed to solving the unsatisfied market and realizing the curve overtaking of new drug research and development. Focusing on the revolutionary technology of organoids, Chuangxin will accelerate the strategic layout and continue to lead the technological development and commercial transformation of organoids!
Dachen Caizhi said that organoid technology has broad application prospects and commercial potential in the fields of clinical medication guidance and new drug research and development. Chuangxin International has profound technology and data accumulation in this field, and has built the world’s leading organoid technology platform. At the same time, its founding team is excellent, complementary and strong in execution, and has a very clear strategic plan for future development. This is the first shot of Dachen needle in the field of organoids, and will firmly go hand in hand with enterprises and grow together. We are very much looking forward to leading organoid technology breakthroughs and product upgrades together with Chuangxin in the future, bringing good news to the majority of tumor patients!
Guangzhou Financial Holding Fund said that Guangzhou Financial Holding Fund attaches great importance to the investment and layout of the biomedical track, especially in the segmented fields such as IVD. At present, Guangzhou Financial Holding Group is the actual controller of Daan Gene, and Guangzhou Financial Holding Fund is also focusing on it. Invested in high-quality IVD projects including Kang Liming, and these projects have grown into leading companies in various sub-tracks. Chuangxin International is another important layout of Guangzhou Financial Holding Fund in the field of precision therapy. With the application of organoid drug susceptibility screening in the field of precision treatment gradually matures, Chuangxin International, as the field of organoids, has advantages in technology, channels and certification, etc. The most leading companies in the field will fully enjoy the dividends of industry development and grow into another leading company in the field of precision therapy. It is expected that the two sides will strengthen cooperation and interaction, and bring organoid technology to the clinic as soon as possible to benefit the society.
The Guangzhou Development Zone Fund stated that organoid technology is a cutting-edge technology of innovative life science and technology that has developed rapidly in recent years, and has immeasurable commercial potential in the fields of clinical application and drug development. As the first enterprise to enter this track, Chuangxin International is a leader among the high-tech enterprises that have grown up in this fertile entrepreneurial soil of Guangzhou. As a local investment institution, the Guangzhou Development Zone Fund will spare no effort to support companies like Chuangxin to become bigger and stronger, and work together for Guangzhou’s status and reputation as an international biomedical technology R&D center!
Wanlian Tianze, a private equity fund subsidiary of Wanlian Securities, and Wanlian Guangsheng, an investment subsidiary, said they were very happy to participate in this round of financing of Chuangxin International. Chuangxin is an innovative biomedical enterprise centered on organoid technology. We are optimistic about the company’s first-mover advantage in the segmented field of organoids. The management team with Professor Deng Chuxia and Dr. Huang Min as the core executives is very strong. After several years of development, the company has built a relatively complete organoid culture system. , AI image quality control, high-efficiency drug susceptibility testing and other technical platforms, especially based on the world’s largest cohort of organoid clinical research and application data in the past, the company is building an organoid big data center, which is bound to be able to effectively promote the company’s organoid related research. The application of products in the field of clinical and new drug research and development of pharmaceutical companies.
Qudao Assets said, congratulations to Chuangxin International on the successful completion of a new round of financing. As the lead investor in the previous round, Qudao Assets continued to follow up the investment in this round to support the development of the company. It is Qudao Assets’ recognition of Chuangxin International’s future and value. , we are firmly optimistic about the broad prospects and market applications of the organoid industry, and are optimistic about its substantial significance in assisting patients in diagnosis and treatment, accelerating preclinical R&D for pharmaceutical companies, and reducing R&D costs. As a leading company in the industry, we expect Chuangxin to continue to maintain rapid growth in business, expand its visibility at the capital level, and gain deeper influence in the medical field, ultimately reflecting its corporate social responsibility and medical mission. Come on, Chuangxin!
attached
For more project information, please go to “Analysis of Rui Beast” .
media coverage
Investment Community Venture Bangtou China Network
Related events
- Chuangxin International received another 100 million yuan in financing2022-10-28
- Chuangxin International completed the A round of financing of nearly 100 million yuan to promote the research and development, upgrading and industrialization of organoids2021-03-12
This article is reprinted from: https://readhub.cn/topic/8ktqbSq9IP2
This site is for inclusion only, and the copyright belongs to the original author.